Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

M Rothenberg; J Cox; C Butts; T Hietanen

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

M Rothenberg, J Cox, C Butts, T Hietanen

Research output: Contribution to journal › Article › Scientific › peer-review

184 Citations (Scopus)

Original language	English
Pages (from-to)	1720-1726
Journal	Annals of Oncology
Volume	19
Issue number	10
Publication status	Published - 2008
Publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://pubmed.ncbi.nlm.nih.gov/18550577

Cite this

@article{c8c98b1d576449089f1c4deea4084c46,

title = "Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study",

author = "M Rothenberg and J Cox and C Butts and T Hietanen",

year = "2008",

language = "English",

volume = "19",

pages = "1720--1726",

number = "10",

}

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. / Rothenberg, M; Cox, J; Butts, C et al.
In: Annals of Oncology, Vol. 19, No. 10, 2008, p. 1720-1726.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

AU - Rothenberg, M

AU - Cox, J

AU - Butts, C

AU - Hietanen, T

PY - 2008

Y1 - 2008

M3 - Article

SN - 1569-8041

VL - 19

SP - 1720

EP - 1726

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -